Uriviga DFZ Tablet combines Tamsulosin 0.4mg and Deflazacort 30mg, a clinically proven urology combination designed to ease ureteric spasm, reduce inflammation, and support the smooth passage of urinary calculi. It is widely prescribed in cases of ureteric colic and post-lithotripsy management.
Tamsulosin, an alpha-1 adrenergic blocker, helps relax the smooth muscles of the urinary tract, improving urine flow and reducing stone-related discomfort. Deflazacort, a corticosteroid, reduces local inflammation and edema, further enhancing stone expulsion and patient comfort.
This combination is commonly recommended by urologists, general physicians, and surgeons for managing urinary stones, benign prostatic hyperplasia–associated symptoms, and acute ureteric pain. Its dual-action approach ensures faster symptom relief and better clinical outcomes.
Adding Uriviga DFZ Tablet to your product range strengthens your urology and renal-care segment, creating strong opportunities in hospital supply, pharmacy distribution, institutional procurement, export markets, and third-party manufacturing. Its consistent demand in urology practice makes it a commercially valuable and high-utility product.